TOP TIERMARKET NEWSWIRE
Movers explained · November 3, 2026

Why Is MADRIGAL PHARMACEUTI (MDGL) Stock Moving Today?

By the Top Tier Newswire AI Desk · August 26, 2026 at 1:48 PM ET · reviewed against 6 wire stories

MADRIGAL PHARMACEUTI (MDGL) is drawing unusual attention today. Our newswire has captured 6 stories on MDGL across 5 sources in the last 36 hours, with AI sentiment reading bullish (avg 61/100).

Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.

MDGL stock rose 5.39% to $539.75 on Friday, driven by a positive analyst upgrade and strong earnings results. The stock opened at $510.14 and reached an intraday high of $539.89 at 1:45 PM ET before closing at $539.50. The move came as Wolfe Research upgraded the stock to Outperform and set a $605 price target.

What Happened

Madrigal Pharmaceuticals stock climbed on the back of a recent upgrade from Wolfe Research, which cited the company’s strong earnings and growth potential. The stock beat expectations in its second-quarter report, with earnings per share of $(1.99) versus an estimate of $(2.50) and revenue of $364.252 million versus an estimate of $353.178 million. Barclays also maintained its Overweight rating but lowered its price target to $962. These developments, combined with positive commentary from The Motley Fool about Rezdiffra’s long-term growth potential, contributed to the stock’s rally.

What The Data Shows

The stock has traded between $393.61 and $615.00 over the past 52 weeks and is currently trading near the upper end of that range. It has posted 22 fresh 52-week highs on August 26. The session saw volume of 0.1 million shares, or 0.3 times the 3-month daily average. Despite the recent rise, the stock remains unprofitable with a trailing twelve-month EPS of -14.22 and a net margin of -25.3%. Recent insider transactions show three sales totaling $2.2 million in the last 90 days, with the most recent on August 20.

What To Watch

Madrigal Pharmaceuticals does not have an upcoming earnings date listed. Investors should monitor the breadth of analyst coverage and any further developments in its drug pipeline or regulatory approvals.

AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.

MDGL by the numbers

Coverage: 6 stories / 5 sourcesAI sentiment: 61/100 (bullish)Mkt cap: $11.8B52w: $393.61 to $615.00
MDGL · today's session (5-min) · +9.64% vs prior close · updated 10:03 AM ET
$424$460$496prev close $431.15$472.717:00 AM7:45 AM8:30 AM9:15 AM10:00 AM7:00 AM · $470.007:10 AM · $475.007:15 AM · $470.007:30 AM · $472.007:40 AM · $492.007:45 AM · $485.007:50 AM · $479.998:05 AM · $477.008:10 AM · $469.998:15 AM · $470.008:20 AM · $450.008:25 AM · $450.008:30 AM · $450.208:35 AM · $459.518:40 AM · $450.638:45 AM · $440.498:50 AM · $430.008:55 AM · $430.009:00 AM · $428.009:05 AM · $428.019:10 AM · $431.109:15 AM · $432.009:20 AM · $435.009:25 AM · $448.009:30 AM · $460.509:35 AM · $460.609:40 AM · $467.829:45 AM · $476.119:50 AM · $475.089:55 AM · $477.0810:00 AM · $472.71
AI sentiment, last 36h · averaged over 6 stories · 61/100 bullish
AI sentiment 61/100 (bullish)0 · bearish50bullish · 100

The headlines behind the move

Story flow · 6 stories on the wire, last 36h · hover or tap a dot for the headline
36h ago24h ago12h agonowSeeking Alpha · sentiment 50 · Madrigal Pharmaceuticals Q3 2026 Earnings PreviewSeeking Alpha · 50Madrigal Pharmaceuticals Q3 2026 Earnings PreviewBusiness Insider · sentiment 74 · Madrigal Pharmaceuticals Reports Third-Quarter 2026 Financial Results and Provides Corporate UpdatesBusiness Insider · 74Madrigal Pharmaceuticals Reports Third-Quarter 2026 Financial Results and Provides Corpor…Seeking Alpha · sentiment 78 · Madrigal PharmaceuticalsEPS of $1.83, revenue of $431.3M beats by $26.18MSeeking Alpha · 78Madrigal PharmaceuticalsEPS of $1.83, revenue of $431.3M beats by $26.18MBarron's · sentiment 38 · S&P 500 Futures Decline in Premarket Trading; Ascendis Pharma, Madrigal Pharmaceuticals LeadBarron's · 38S&P 500 Futures Decline in Premarket Trading; Ascendis Pharma, Madrigal Pharmaceuticals LeadThe Fly · sentiment 74 · Madrigal Pharmaceuticals reports Q3 EPS $1.83, consensus ($1.09)The Fly · 74Madrigal Pharmaceuticals reports Q3 EPS $1.83, consensus ($1.09)SEC 8-K · sentiment 50 · MADRIGAL PHARMACEUTICALS, INC. (MDGL) files 8-KSEC 8-K · 50MADRIGAL PHARMACEUTICALS, INC. (MDGL) files 8-K
2h agoSEC 8-KNEUTRAL 50General

MADRIGAL PHARMACEUTICALS, INC. (MDGL) files 8-K

Filed: 2026-11-03 AccNo: 0001628280-26-069093 Size: 611 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

2h agoThe FlyBULLISH 74Earnings

Madrigal Pharmaceuticals reports Q3 EPS $1.83, consensus ($1.09)

2h agoBarron'sBEARISH 38General

S&P 500 Futures Decline in Premarket Trading; Ascendis Pharma, Madrigal Pharmaceuticals Lead

3h agoSeeking AlphaBULLISH 78Earnings

Madrigal PharmaceuticalsEPS of $1.83, revenue of $431.3M beats by $26.18M

Madrigal Pharmaceuticals Q3 revenue jumped 50% as Rezdiffra demand surged and profitability began.

3h agoBusiness InsiderBULLISH 74Earnings

Madrigal Pharmaceuticals Reports Third-Quarter 2026 Financial Results and Provides Corporate Updates

Third-quarter 2026 Rezdiffra ® (resmetirom) net sales of $431.3 million, representing year-over-year growth of 50%; achieved first quarter of profitability...

1d agoSeeking AlphaNEUTRAL 50Earnings

Madrigal Pharmaceuticals Q3 2026 Earnings Preview

Madrigal Pharmaceuticals reports Q3 earnings Tuesday before the open.

Frequently asked questions

Why is MDGL stock moving today?

MADRIGAL PHARMACEUTI (MDGL) is drawing unusual attention today. Our newswire has captured 6 stories on MDGL across 5 sources in the last 36 hours, with AI sentiment reading bullish (avg 61/100). The most recent driver: "MADRIGAL PHARMACEUTICALS, INC. (MDGL) files 8-K" (SEC 8-K).

Is MDGL a buy right now?

Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of MDGL coverage reads 61/100 over 6 stories; treat it as a research signal and do your own diligence.

How fast does this page update?

The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.

More moves explained today

Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →

More on MDGL: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.

Earlier MDGL move explainers: 2026-08-26